Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

• the present invention provides the citrate salt of (4-((3i?,4i?)-3-methoxytetrahydro- pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone and to a process for manufacturing it.
• the present invention also provides the same citrate salt for use in the treatment of medical conditions, such as acute and chronic mild to moderate musculoskeletal pain, low back pain, chronic low back pain, pain related to rheumatoid arthritis, shoulder pain, dental pain, signs and symptoms of osteoarthritis, osteoarthritis of the knee, osteoarthritis of the hip, osteoarthritis of the hand, pain associated with osteoarthritis, cancer pain, diabetic polyneuropathy, visceral pain, acute pain, diabetic nephropathy, neuropathic pain, as well as to a pharmaceutical composition comprising the same salt.
• medical conditions such as acute and chronic mild to moderate musculoskeletal pain, low back pain, chronic low back pain, pain related to rheumatoid arthritis, shoulder pain, dental pain, signs and symptoms of osteoarthritis, osteoarthritis of the knee, osteoarthritis of the hip, osteoarthritis of the hand, pain associated with osteoarthritis, cancer pain, diabetic polyneuropathy, visceral pain, acute pain
• WO 201 1/073154 discloses a number of tetrahydropyranyl-methyl-amino- (hetero)aryl-amides without disclosing any specific salt or crystal form of the compounds exemplified therein.
• WO 2011/073154 discloses compound I
• CMC chemistry, manufacturing and controls
• the objective technical problem underlying the present invention is to provide a drug substance with CCR2 antagonistic activity which is developable for use as a medicament in humans, i.e., where:
• the drug substance is characterised by high pharmacological potency, efficacy, in vitro and in vivo pharmacokinetics, and necessary safety properties;
• CMC chemistry, manufacturing and controls
• Compound I has surprisingly been found to fulfil the majority of the above mentioned criteria required for use as a medicament in humans as demonstrated (see biological data below). These parameters include plasma protein binding (relevant for pharmacokinetics and pharmacodynamics), in vitro metabolic stability (relevant for pharmacokinetics), pharmacokinetics and safety properties (hERG, relevant for cardiovascular safety, and drug- induced phospholipidosis).
• the free base of compound I however turned out to be an amorphous material which was in a metastable state and thus subject to metamorphosis. It was not suitable as a drug substance for development because it did not fulfil the requirement of being able to be reproducibly manufactured.
• the drug substance must invariably be obtained in a well-defined crystalline modification.
• a crystalline form of a drug substance or its salt exists in different polymorphic modifications (polymorphism)
• spontaneous conversion of one polymorphic form into another one may occur.
• Such a spontaneous interconversion cannot be tolerated and should be avoided by all means. Therefore, it is essential for securing the reproducibility of the pharmaceutical manufacturing process to identify a salt of a drug substance that exists either in one crystalline form only, or that at least is characterized by a reduced tendency towards polymorphism.
• the citrate salt 1 is crystalline, i.e., defined by a specific crystal modification, thus allowing to obtain the drug substance in high purity and reproducibly high stability.
• Another key parameter of a drug substance is hygroscopicity.
• Water uptake of a salt of a drug substance by sorption during manufacture leads to a reduced amount of the drug substance in the drug product and therefore to reduced efficacy.
• water uptake of a salt of a drug substance or a drug product may lead to decomposition of the drug substance. Therefore, it is essential to identify a drug substance or salt thereof that is not hydroscopic, or has only very little hygroscopic character.
• the crystalline form of the citrate salt 1 of compound I is characterized by low and reversible water uptake at a relative humidity of up to 90% (2.6% water uptake at 80% relative humidity and 3.4% water uptake at 90% relative humidity).
• the crystalline forms of the corresponding hydrobromide, hydrochloride, esilate and methanesulfonate of compound I readily absorb significant amounts of water at a relative humidity of as low as 80% and become irreversibly deliquescent.
• the compound is provided in crystalline form.
• Another aspect of the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising (i) a compound described herein such as citrate salt 1 and (ii) one or more carriers and/or diluents.
• the pharmaceutical composition is formulated for oral administration.
• Another aspect of the invention provides the citrate salt 1 or a pharmaceutical composition comprising said citrate salt 1 for use in treating a medical condition.
• exemplary medical conditions include, for example, treatment of pain (e.g., inflammatory pain or neuropathic pain) and osteoarthritis.
• Another aspect of the invention provides a method of treating a medical condition in a patient, where the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound described herein, such as citrate salt 1, in order to treat the medical condition.
• a compound described herein such as citrate salt 1
• exemplary medical conditions include, for example, pain (e.g., inflammatory pain or neuropathic pain) and osteoarthritis.
• Figure 1 shows the X-ray powder diffractogram of the amorphous base of the compound (4-((3i?,4i?)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6- (((2i?,6 ⁇ -6-(p4olyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone.
• Figure 2 shows the X-ray powder diffractogram of (4-((3i?,4i?)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrirnidin-4-yl)methanone citrate.
• Figure 3 shows the thermoanalysis and determination of the melting point
• Figure 4 shows the sorption isotherms of (4-((3i?,4i?)-3-methoxytetrahydro-pyran- 4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone citrate.
• Figure 5 shows the X-ray powder diffractogram of (4-((3i?,4i?)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2i?,65)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone hydrobromide.
• Figure 6 shows the thermoanalysis and determination of the melting point
• Figure 7 shows the sorption isotherms of (4-((3i?,4i?)-3-methoxytetrahydro-pyran- 4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone hydrobromide.
• Figure 8 shows the X-ray powder diffractogram of (4-((3i?,4i?)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2i?,65)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone hydrochloride.
• Figure 10 shows the sorption isotherms of (4-((3i?,4i?)-3-methoxytetrahydro-pyran- 4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone hydrochloride.
• Figure 11 shows the X-ray powder diffractogram of (4-((3i?,4i?)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2i?,65)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone esilate.
• Figure 12 shows the thermoanalysis and determination of the melting point (DSC/TG) of (4-((3i?,4i?)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6- (((2i?,6 ⁇ -6-(p4olyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone esilate.
• Figure 13 shows the sorption isotherms of (4-((3i?,4i?)-3-methoxytetrahydro-pyran- 4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone esilate.
• Figure 14 shows the X-ray powder diffractogram of (4-((3i?,4i?)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone methanesulfonate.
• Figure 15 shows the thermoanalysis and determination of the melting point (DSC/TG) of (4-((3i?,4i?)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6- (((2i?,6 ⁇ -6-(p4olyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone methanesulfonate.
• Figure 16 shows the sorption isotherms of (4-((3i?,4i?)-3-methoxytetrahydro-pyran- 4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone methanesulfonate.
• Figure 17 shows the FT-RAMAN spectrum of (4-((3i?,4i?)-3-methoxytetrahydro- pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone citrate.
• Figure 18 shows the FT-RAMAN spectrum of (4-((3i?,4i?)-3-methoxytetrahydro- pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone esilate.
• the invention provides salt forms of 4-((3R,4R)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing such salt forms, methods for preparing salt forms, and therapeutic methods for using such salt forms, such as in the treatment of pain and other medical conditions.
• the citrate salt of 4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6- (((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone was surprisingly discovered to provide multiple unexpected benefits over other salt forms of 4- ((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone.
• the citrate salt of 4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6- (((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylandno)pyrimidin-4-yl)methanone was found to exhibit low and reversible water uptake at a relative humidity up to 90%, which stands in contrast to salt forms of the corresponding hydrobromide, hydrochloride, esilate, and methanesulfonate that readily absorb significant amounts of water at a relative humidity of as low as 80% and become irreversibly deliquescent.
• citrate salt of 4-((3R,4R)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone was unexpectedly found to exhibit only one polymorphic crystalline form, which stands in contrast to the corresponding crystalline salts formed from hydrobromic acid and hydrochloric acid that exhibited different polymorphic modifications.
• the citrate salt of 4-((3R,4R)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylandno)pyrimidin-4-yl)methanone is surprisingly superior for development as a pharmaceutical due to the multiple unexpected properties that are beneficial.
• subject and patient refer to organisms to be treated by the methods of the present invention.
• organisms include mammals (e.g. , murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably is humans.
• the term "effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results.
• An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
• the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
• compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
• One aspect of the invention provides salt forms of 4-((3R,4R)-3-methoxytetrahydro- pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone.
• this disclosure describes salt forms of 4-((3i?,4i?)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65 -6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone prepared by reacting 4-((3i?,4i?)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2i?,65)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrirnidin-4-yl)methanone with an acid selected from citric acid, hydrobromic acid, hydrochloric acid, ethanesulfonic acid, and methanesulfonic acid.
• an acid selected from citric acid, hydro
• the citrate salt of 4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l- yl)(5-methyl-6-(((2R,6S)-6-(p olyl)tetrahydro-2H-pyran-2-yl)methylandno)pyrimidin-4- yl)methanone was found to exhibit low and reversible water uptake at a relative humidity up to 90%, which stands in contrast to salt forms of the corresponding hydrobromide, hydrochloride, esilate, and methanesulfonate that readily absorb significant amounts of water at a relative humidity of as low as 80% and become irreversibly deliquescent.
• citrate salt of 4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2R,6S)-6- (p-tolyl)tetrahydro-2H-pyran-2-yl)methylaiTiino)pyrimidin-4-yl)methanone was unexpectedly found to exhibit only one polymorphic crystalline form, which stands in contrast to the corresponding crystalline salts formed from hydrobromic acid and hydrochloric acid that exhibited different polymorphic modifications.
• the citrate salt of 4-((3R,4R)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylandno)pyrimidin-4-yl)methanone is surprisingly superior for development as a pharmaceutical due to the multiple unexpected properties that are beneficial.
• one aspect of the invention provides the citrate salt of compound I:
• said citrate salt is in crystalline form.
• the crystalline form is characterized in that the X-ray powder diffraction pattem further comprises a peak at 12.2°.
• the crystalline form is,
• the X-ray powder diffraction pattern further comprises a peak at 13.7°.
• the crystalline form is characterized in that the X-ray powder diffraction pattern further comprises a peak at 14.6°.
• the crystalline form is characterized in that the X-ray powder diffraction pattern further comprises a peak at 18.7°.
• the crystalline form is characterized in that the X-ray powder diffraction partem further comprises a peak at 24.6°.
• the crystalline form is characterized in that X-ray powder diffraction pattern further comprises a peak at 26.3°.
• the crystalline form exhibits a X-ray powder diffraction partem comprising peaks at the following 2-theta values measured using
• the relative intensity of the peak at said diffraction angles 2-theta is at least 10%. In certain other embodiments, the relative intensity of the peak at said diffraction angles 2-theta is at least 15%.
• the crystalline form has a X-ray powder diffraction partem that is substantially as shown in Figure 2.
• the crystalline form is characterized by the following X-ray powder diffraction pattern expressed in terms of diffraction angle 2 ⁇ , inter-planar distances d, and relative intensity (ex ressed as a percentage with respect to the most intense peak):
• the crystalline form may be further characterized according to its Raman spectrum. Accordingly, in certain embodiments, the crystalline form has a Raman spectrum comprising peaks at any one or all of the following Raman shifts expressed in wavenumbers in cm "1 : 1718, 1242, 731 , 662, 553.
• the crystalline form may be further characterized according to its melting point. Accordingly, in certain embodiments, the crystalline form has a melting point of 212 ⁇ 5°C.
• the crystalline form may be further characterized according to its differential scanning calorimetry curve. Accordingly, in certain embodiments, the crystalline form has a differential scanning calorimetry curve substantially the same as shown in Figure 3.
• the molar ratio of citric acid to 4-((3R,4R)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrirnidin-4-yl)methanone is about 1 : 1 in a citrate salt of 4-((3R,4R)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylaniino)pyrirnidin-4-yl)methanone.
• the molar ratio of citric acid to 4-((3R,4R)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone is in the range of 1.2 : 1 to 1 : 1.2 in a citrate salt of 4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-l-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrirnidin-4-yl)methanone.
• the molar ratio of citric acid to 4-((3R,4R)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrirnidin-4-yl)methanone is 1 : 1 in a citrate salt of 4-((3R,4R)-3- methoxytetrahydro-pyran-4-ylamino)piperidin-l -yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrirnidin-4-yl)methanone.
• Methods for preparing citrate salt 1 are also provided.
• one aspect of the invention provides a method for preparing compound 1
• the method is further characterized in that the organic solvent in step a) is selected from the group consisting of ethyl acetate, isopropanol and a mixture of isopropanol and water.
• Compounds such as those described in Section I e.g., citrate salt 1 and pharmaceutical compositions described herein are useful as a medicament.
• the medicament may be for treating a disorder in which inhibition of CCR2 activity provides a therapeutic benefit.
• Chemokine receptor CCR2 has been reported to be implicated as being an important mediator of inflammatory and immunoregulatory disorders and diseases as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. See, for example, WO 2010/070032. Thus, agents that modulate the chemokine receptor CCR2 are useful in treating such disorders and diseases.
• CCR2 is a critical regulator of monocytes trafficking, which can be described as the movement of the monocytes towards an inflammation along a gradient of monocyte chemoattractant proteins (MCP-1, MCP-2, MCP-3, MCP-4).
• one aspect of the invention provides a method of treating a CCR2- related condition in a patient, where the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound described herein (e.g., the citrate salt 1 or a crystalline form thereof) to treat the condition.
• a compound described herein e.g., the citrate salt 1 or a crystalline form thereof
• the CCR2- related condition is a MCP-1 related condition.
• the CCR2-related condition is pain.
• exemplary types of pain contemplated for treatment include, for example, inflammatory pain, neuropathic pain, and visceral pain.
• the pain is chronic pain.
• the pain is pain due to osteoarthritis.
• pain contemplated for treatment include, for example, low back pain, hip pain, leg pain, non-herpetic neuralgia, post herpetic neuralgia, diabetic neuropathy, nerve injury -induced pain, acquired immune deficiency syndrome (AIDS) related neuropathic pain, head trauma, toxin and chemotherapy caused nerve injuries, phantom limb pain, painful traumatic mononeuropathy, painful polyneuropathy, thalamic pain syndrome, post-stroke pain, central nervous system injury, post surgical pain, carpal tunnel syndrome, trigeminal neuralgia, post mastectomy syndrome, postthoracotomy syndrome, stump pain, repetitive motion pain, neuropathic pain associated hyperalgesia and allodynia, alcoholism and other drug-induced pain.
• AIDS acquired immune deficiency syndrome
• the CCR2-related condition is an immune related disease.
• immune-related diseases include, for example, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondilitis, gastric ulcer, seronegative arthropathies, osteoarthritis, inflammatory bowel disease, and ulcerative colitis.
• the CCR2-related condition is a fibrotic condition.
• exemplary fibrotic conditions include, for example, liver fibrosis (including but not limited to alcohol-induced cirrhosis, viral-induced cirrhosis, autoimmune- induced hepatitis); lung fibrosis (including but not limited to scleroderma, idiopathic pulmonary fibrosis); kidney fibrosis (including but not limited to scleroderma, diabetic nephritis, glomerular pehpritis, lupus nephritis); dermal fibrosis (including but not limited to scleroderma, hypertrophic and keloid scarring, burns); myelofibrosis; neurofibromatosis; fibroma; intestinal fibrosis; and fibrotic adhesions resulting from surgical procedures.
• the CCR2 -related condition is an inflammatory disorder.
• Another aspect of the invention provides a method of treating a condition selected from pain, osteroarthritis, diabetic nephropathy, and diabetic polyneuropathy, where the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound described herein (e.g., the citrate salt 1 or a crystalline form thereof) to treat the condition.
• a compound described herein e.g., the citrate salt 1 or a crystalline form thereof
• the condition is pain. In certain embodiments, the condition is inflammatory pain. In certain embodiments, the condition is chronic pain. In certain embodiments, the condition is pain due to osteoarthritis. In certain embodiments, the condition is neuropathic pain or visceral pain.
• the condition is selected from the group consisting of acute and chronic mild to moderate musculoskeletal pain, low back pain, chronic low back pain, pain related to rheumatoid arthritis, shoulder pain, dental pain, signs and symptoms of osteoarthritis, osteoarthritis of the knee, osteoarthritis of the hip, osteoarthritis of the hand, pain associated with osteoarthritis, cancer pain, diabetic polyneuropathy, visceral pain, acute pain, diabetic nephropathy, and neuropathic pain.
• the condition is pain selected from (a) trigeminal neuralgia and (b) pain due to chemotherapy caused nerve injury.
• the condition is osteoarthritis.
• the method comprises administering to the patient a therapeutically effective amount of citrate salt 1 to treat the condition.
• the invention provides for using a compound described herein for the treatment of a disease in which inhibition of the CCR2 receptor is beneficial, such as: (i) acute and chronic mild to moderate musculoskeletal pain (low back pain, chronic low back pain, pain related to rheumatoid arthritis, shoulder pain, dental pain); (ii) signs and symptoms of osteoarthritis (osteoarthritis of the knee and/or hip, osteoarthritis of the hand, pain associated with osteoarthritis); (iii) cancer pain; (iv) diabetic polyneuropathy; (v) visceral pain, (vi) acute pain, (vii) diabetic nephropathy; and (viii) neuropathic pain.
• a disease in which inhibition of the CCR2 receptor is beneficial such as: (i) acute and chronic mild to moderate musculoskeletal pain (low back pain, chronic low back pain, pain related to rheumatoid arthritis, shoulder pain, dental pain); (ii) signs and symptoms of osteoarthritis (osteo
• Another aspect of the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound described herein (e.g., citrate salt 1) together with one or more inert carriers and/or diluents.
• the pharmaceutical compositions may be formulated for administration via a particular route, such as oral administration.
• suitable forms for administration are, for example, tablets, capsules, solutions, syrups, emulsions or inhalable powders or aerosols.
• suitable forms for administration are, for example, tablets, capsules, solutions, syrups, emulsions or inhalable powders or aerosols.
• pharmaceutically effective compound(s) in each case should be in the range from 0.1 to 90 wt.%, preferably 0.5 to 50 wt.% of the total composition, i.e., in amounts which are sufficient to achieve the dosage range specified hereinafter.
• the preparations may be administered orally in the form of a tablet, as a powder, as a powder in a capsule (e.g. a hard gelatine capsule), as a solution or suspension.
• a tablet e.g. a powder
• a capsule e.g. a hard gelatine capsule
• the active substance combination may be given as a powder, as an aqueous or aqueous-ethanolic solution or using a propellant gas formulation.
• Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
• the tablets may also comprise several layers. Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
• excipients for example inert
• Syrups containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxy methyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as />-hydroxybenzoates.
• a sweetener such as saccharine, cyclamate, glycerol or sugar
• a flavour enhancer e.g. a flavouring such as vanillin or orange extract.
• suspension adjuvants or thickeners such as sodium carboxy methyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as />-hydroxybenzoates.
• Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
• Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or poly ethylenegly col or the derivatives thereof.
• Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and
• pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins,
• polyvinylpyrrolidone polyvinylpyrrolidone
• lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate.
• the tablets may, of course, contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and di calcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like.
• additives such as sodium citrate, calcium carbonate and di calcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like.
• lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process.
• the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
• kits for treating a medical condition comprises: i) instructions for treating a medical condition, such as pain, osteroarthritis, diabetic nephropathy, or diabetic polyneuropathy (for example, pain such as selected from acute and chronic mild to moderate musculoskeletal pain, low back pain, chronic low back pain, pain related to rheumatoid arthritis, shoulder pain, dental pain, pain associated with osteoarthritis, cancer pain, visceral pain, acute pain, diabetic nephropathy, and neuropathic pain); and ii) a compound described herein, such as citrate salt 1.
• the kit may comprise one or more unit dosage forms containing an amount of citrate salt 1 that is effective for treating said medical condition, such as pain.
• MRTdisp mean residence time following intravenous dosing
• MRTtot mean residence time following oral dosing
• Samples have been measured in boiling point tubes using a Bruker RAM II FT- Raman Module instrument, resolution 2 cm “1 , 64 scans, laser power 500 mW (focussed laser). Analysis: scaling of vector in spectral range 3500 cm “1 - 50 cm “1 .
• the compounds are characterised by a melting point determined by Differential Scanning Calorimetry (DSC), evaluated by the peak maximum or onset temperature.
• the heating rate of the experiment is 10°C/min.
• the values given were determined using a DSC instrument from the Q-seriesTM of TA Instruments.
• TA Instruments This method measures weight changes in a material as a function of temperature under a controlled atmosphere.
• Sorption isotherms were generated using an IGAsorp water sorption monitor from Hiden Isochema. Adsorption and desorption isotherms were obtained at 25°C with 10 % r.h. step intervals ranging from 10 % r.h. to 90 % r.h.
• Solubility was determined using an automated shake flask method (at room temperature) and quantitation of the dissolved drug substance was determined by UV- spectroscopy within this automated setup.
• citric acid mono hydrate (78.2 mg; 0.372 mmol). The solution is stirred overnight (18 h). The suspension is filtered and the product is dried at 40°C in vacuo to yield 140 mg 0.192 mmol (52%) colourless crystals. Physical characterization data for citrate salt 1 is provided below.
• the resulting suspension is diluted with 60 L of isopropyl alcohol within 1 h at 55 °C and then cooled to 20 °C within 3 h. Then, the suspension is stirred for 17 h at 20 °C and isolated by filtration. The filter cake is washed twice with a mixture of 19 L of isopropyl alcohol and 1 L of water, each. The product is dried at 50 °C in vacuo to yield 17.76 kg of compound (83 %). Physical characterization data for citrate salt 1 is provided below.
• NMR ( 1 C, 100 MHz, DMSO-d 6 ): 176.6, 171, 165.4, 161.0, 156.6, 155.4, 140.3, 136.0, 128.5, 125.6, 109.3, 78.5, 75.4, 72.4, 72.2, 71.2, 64.8, 64.4, 64.4, 55.5, 55.5, 51.5, 51.4, 50.2, 45.6, 44.1, 44.1, 38.8, 33.3, 29.6, 28.7, 28.7, 25.1, 23.1, 20.6, 11.7 (includes rotamers).
• Table I shows the solubility of (4-((3i?,4i?)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l -yl)(5-methyl-6-(((2i?,65 -6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone citrate in different aqueous media at 2, 4 and 6 h.
• Table I shows the solubility of (4-((3i?,4i?)-3-methoxytetrahydro-pyran-4- ylamino)piperidin-l -yl)(5-methyl-6-(((2i?,65 -6-(p-tolyl)tetrahydro-2H-pyran-2- yl)methylamino)pyrimidin-4-yl)methanone citrate in different aqueous media at 2, 4 and 6 h.
• citrate salt 1 Various solid state properties of citrate salt 1 are described below.
• Citrate salt 1 is highly crystalline as can be seen in the X-ray powder diffraction diagram in Figure 2.
• the X-ray powder reflection and intensities (standardised) are shown in Table II.
• salt 1 is in crystalline form.
• the crystalline form shows a X-ray powder diffraction pattern further comprising a peak at 12.2°.
• the crystalline form shows a X-ray powder diffraction pattern further comprising a peak at 13.7°.
• the crystalline form shows a X-ray powder diffraction pattern further comprising a peak at 14.6°.
• the crystalline form shows a X-ray powder diffraction pattern further comprising a peak at 18.7°.
• the crystalline form shows a X-ray powder diffraction pattern further comprising a peak at 24.6°.
• the crystalline form shows a X-ray powder diffraction pattern further comprising a peak at 26.3°.
• the crystalline form shows a Raman spectrum comprising peaks at any one or all of the following Raman shifts expressed in wavenumbers in cm "1 : 1718, 1242, 731, 662, 553.
• the crystalline form shows a melting point of 212 ⁇ 5°C.
• the citrate salt 1 may be provided in a pharmaceutical composition. Accordingly, another aspect of the present invention is a pharmaceutical composition containing the salt according to any one of the preceding embodiments optionally together with one or more inert carriers and/or diluents.
• hydrobromide salt of compound of formula (I) is of medium crystallinity as demonstrated in the X-ray powder diffraction diagram in Figure 5.
• the X-ray powder reflection and intensities (standardised) are shown in Table III.
• hydrochloride salt of compound of formula (I) is of medium crystallinity as can be seen in the X-ray powder diffraction diagram in Figure 8.
• the X-ray powder reflection and intensities (standardised) are shown in Table IV. Table IV.
• the esilate salt of compound of formula (I) is of high crystallinity as can be seen in the X-ray powder diffraction diagram in Figure 11.
• the X-ray powder reflection and intensities (standardised) are shown in Table V.
• the methanesulfonate salt of compound of formula (I) is of medium crystallinity as can be seen in the X-ray powder diffraction diagram in Figure 14.
• the X-ray powder reflection and intensities (standardised) are shown in Table VI.
• a broad endothermic effect occurs between 40 - 80 °C.
• a weak endothermic effect occurs between 130 - 150 °C (2.8% weight loss on drying).
• a weak broad endothermic effect occurs between 40 - 100 °C. 2.4% loss on drying is correlated with the endothermic effect.
• EXAMPLE 2 Biological Activity Data Characterizing Compound I and Its Citrate Salt 1 [00160] Experiments were performed to evaluate the biological activity of compound I and its citrate salt 1. A description of the experimental procedures and results are provided below. Part I: Description of Biological Assays
• Dianorm Teflon dialysis cells (micro 0.2) are used. Each cell consists of a donor (i.e., buffer chamber) and an acceptor chamber (i.e., plasma chamber), separated by an ultrathin semipermeable membrane with a 5 kDa molecular weight cutoff. Stock solutions for each test compound are prepared in DMSO at 1 mM and diluted to a final concentration of 1.0 ⁇ . Aliquots of 200 dialysis buffer (100 mM potassium phosphate, pH 7.4) are dispensed into the buffer chamber. Aliquots of 200 test compound dialysis solution are dispensed into the plasma chambers. Incubation is carried out for 2 hours under rotation at 37°C.
• the dialysate is transferred into reaction tubes.
• the tubes for the buffer fraction contain 0.2 mL acetonitril/water (80/20 volume/volume). Aliquots of 25 ⁇ of the plasma dialysate are transferred into deep well plates and mixed with 25 ⁇ acetonitril/water (80/20
• %bound (plasma concentration - buffer concentration/ plasma concentration) x 100.
• CO initial concentration in the incubation [ ⁇ ]
• CD cell density of vital cells [10e6cells/mL]
• AUD area under the data [ ⁇ x h]
• clast concentration of last data point [ ⁇ ]
• k slope of the regression line for parent decline [h-1].
• the calculated in vitro hepatic intrinsic clearance can be scaled up to the intrinsic in vivo hepatic Clearance and used to predict hepatic in vivo blood clearance (CL) by the use of a liver model (well stirred model).
• mice and rats had food and water available ad libitum.
• the p.o. dose of the compound was usually administered as suspension in 0.5% Natrosol or as a 0.5% Natrosol / 0.015% Tween 80 suspension.
• the doses were applied as a solution in 0.9% NaCL, or as a solution containing 9.1 % HP-beta Cyclodextrin in water.
• test compound plasma was transferred into PCR plates. All samples were stored at approximately -20° C until bioanalytics. The test compound concentrations in plasma were determined by HPLC MS/MS. The lower limit of quantification was between 0.5 nmol/L and 1 nmol/L.
• HEK (human embryonic kidney) 293 cells were stably transfected with hERG cDNA. Cells determined for use in patch clamp experiments were cultivated without antibiotic. Pipettes and Solutions
• Membrane currents were recorded using an EPC-10 patch clamp amplifier (HEKA Electronics, Lambrecht, Germany) and PatchMaster software (HEKA). The current signals were Bessel filtered at 2.5 kHz before being digitized at 5 kHz.
• hERG-mediated membrane currents were recorded at typically 28 °C, using the whole-cell configuration of the patch-clamp technique.
• Transfected HEK293 cells were clamped at a holding potential of -60 mV and hERG-mediated inactivating tail currents were elicited using a pulse partem with fixed amplitudes (activation/inactivation: 40 mV for 2000 ms; recovery: 120 mV for 2 ms; ramp to 40 mV in 2 ms; inactivating tail current: 40 mV for 50 ms) repeated at 15 s intervals.
• 4 pulses scaled down by a factor of 0.2 were recorded for a P/n leak subtraction procedure.
• R s compensation was employed up to a level that safely allowed recording devoid of ringing. The remaining uncompensated R s was recorded as well as actual temperature and holding current.
• concentrations of the test item were applied sequentially on each of the different cells investigated.
• a steady state level of baseline current was measured for at least 90 s prior to the application of the first test article concentration.
• test item was dissolved in DMSO to yield a stock solution of 1000-fold the highest final concentration. This stock was diluted further in DMSO to stock solutions of 1000- fold the remaining final concentrations. Final dilutions in extracellular buffer were prepared freshly from these stocks by a 1 : 1000 dilution step each before starting the experiments. Data Analysis:
• Peak current amplitudes were measured 3 ms after the ramp to +40 mV. For baseline and each concentration the peak currents of the three last sweeps before application of the next concentration were averaged. Residual currents (I/Io) were calculated for each cell as the fraction of actual average peak current and average baseline peak current. Current inhibition was expressed as (1 - I/Io) * 100%. Current inhibition for all cells is reported as mean ⁇ SD. From mean current inhibition data, the IC5 0 is estimated based on the Hill equation using a least squares procedure.
• Cell line U937.
• Cell density 0.5 Mio. cells/mL.
• Amount of medium 3 mL/well.
• PI stock solution 1 mg/mL PBS (stored at 4°C in the dark).
• PI ready to use solution stock solution 1 : 100 diluted with PBS (freshly prepared for each experiment).
• NR stock solution 1 mg/mL DMSO (stored at 4°C in the dark).
• NR ready to use solution for live cell staining NR stock solution 1 : 100 diluted with PBS (freshly prepared for each experiment).
• Nile Red stock solution (cone. 1 mg/mL) : solve 1 mg Nile Red in 1 mL 100% DMSO, store at 2 - 8°C.
• Nile Red working solution for fixed cell staining (cone. 1 ⁇ g/mL): dilute Nile Red stock solution in 1 x PBS (dilution ratio 1 : 1000). The working solution must be prepared and used immediately before staining the cells.
• Cell harvesting may be performed as follows:
• the time to measure 10,000 cells correlates to cell density in the sample.
• Cut-off gates for the fluorescence-dependent differentiation between life and dead cells are defined based on the analysis of cell culture medium plus vehicle exposed Control cells. Cells with a fluorescence lower than the cut-off are defined as viable. Absolute viability of a sample is the relation of viable cells to total cell number and expressed as percentage.
• Samples of less than 90% relative viability are excluded from analysis of the phospholipidogenic potential of a test compound. Samples with a viability between 90 to 95% are selected for assessment case by case depending on the consistency of all analyzed parameters and the absolute fluorescence intensity.
• Compound I inhibited the hERG-mediated potassium current with IC5 0 > 30 ⁇ (12% inhibition at 10 ⁇ , 28% inhibition at 30 ⁇ ).
• Compound I shows the propensitiy to be phospholipidogenic in the in vitro Phospholipidosis assay; the lowest phospholipidogenic concentration of compound I in this in vitro assay is 200 ⁇ .

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=53502570

Family Applications (1)

Country Status (13)

Cited By (6)

Families Citing this family (2)

Citations (1)

Family Cites Families (123)

• 2016
  • 2016-07-01 BR BR112017028492-8A patent/BR112017028492B1/pt active IP Right Grant
  • 2016-07-01 PT PT168188985T patent/PT3317270T/pt unknown
  • 2016-07-01 EP EP16818898.5A patent/EP3317270B1/en active Active
  • 2016-07-01 MX MX2017017177A patent/MX383744B/es unknown
  • 2016-07-01 CN CN201680045214.8A patent/CN108026087B/zh active Active
  • 2016-07-01 PL PL16818898T patent/PL3317270T3/pl unknown
  • 2016-07-01 ES ES16818898T patent/ES2811098T3/es active Active
  • 2016-07-01 CA CA2990460A patent/CA2990460C/en active Active
  • 2016-07-01 WO PCT/US2016/040728 patent/WO2017004537A1/en not_active Ceased
  • 2016-07-01 JP JP2017568018A patent/JP6917910B2/ja active Active
  • 2016-07-01 AU AU2016287584A patent/AU2016287584B2/en active Active
• 2017
  • 2017-12-21 US US15/849,929 patent/US10213428B2/en active Active
  • 2017-12-24 IL IL256530A patent/IL256530A/en active IP Right Grant
• 2018
  • 2018-12-19 US US16/224,902 patent/US10568885B2/en active Active
• 2020
  • 2020-02-11 US US16/787,433 patent/US11147814B2/en not_active Expired - Fee Related
• 2021
  • 2021-10-13 US US17/500,367 patent/US12076321B2/en active Active

Patent Citations (1)

Also Published As

Similar Documents

Legal Events